2019
Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA, Wilson LE, Reed SD. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal Of The National Comprehensive Cancer Network 2019, 17: 245-254. PMID: 30865923, DOI: 10.6004/jnccn.2018.7097.Peer-Reviewed Original ResearchConceptsLow-risk diseaseHigh-risk patientsHigh-risk diseaseRS testingMedicare beneficiariesPrimary analysisEstrogen receptor-positive breast cancerReceptor-positive breast cancerLower chemotherapy useIntermediate-risk diseaseIntermediate-risk patientsRetrospective cohort studyGenomic testingSEER-Medicare dataChemotherapy useCohort studyMultivariable analysisBreast cancerChemotherapy costsLow overall useMAIN OUTCOMEMedicare populationPatientsHigher overall costsDisease
2017
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset
Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Research And Treatment 2017, 162: 1-10. PMID: 28064383, PMCID: PMC5909985, DOI: 10.1007/s10549-016-4093-4.Peer-Reviewed Original ResearchConceptsIntermediate-risk diseaseOncotype DX recurrence scoreHigh-risk diseaseDX recurrence scoreODX RSReceptor statusRecurrence scoreSurrogate markerProgesterone receptor statusInvasive breast cancerEstrogen receptor statusHigh-risk groupOngoing clinical trialsMagee EquationsPresence of patientsAdjuvant chemotherapyClinicopathologic dataRetrospective studyTumor sizeHER2 statusHistopathologic variablesClinical trialsBreast cancerPatient managementAdditional independent validation
2016
How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer
Robinson TJ, Thomas S, Dinan MA, Roman S, Sosa JA, Hyslop T. How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer. Journal Of Clinical Oncology 2016, 34: 3434-3439. PMID: 27528716, PMCID: PMC6366339, DOI: 10.1200/jco.2016.67.6437.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerOccult nodal diseaseLymph nodesThyroid cancerNodal diseaseTumor stageNumber of LNsProphylactic central neck dissectionAdjuvant radioactive iodineLymph node examinationIntermediate-risk diseaseNational Cancer DatabaseMore lymph nodesNode-positive diseasePathologic tumor stagePrimary tumor stageCentral neck dissectionLymph node yieldLN yieldAdult patientsLN evaluationNeck dissectionNodal positivityNode examinationOccult disease
2015
Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGuideline AdherenceHealthcare DisparitiesHumansMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypePractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsRacial GroupsResidence CharacteristicsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsIntermediate-risk diseaseBreast cancerRecurrence scoreClinical practiceNode-negative breast cancerNational Comprehensive Cancer NetworkAdjuvant chemotherapy useIncident breast cancerComprehensive Cancer NetworkEnd Results (SEER) dataHigh-grade diseaseRetrospective observational studyRoutine clinical practiceTumor histologic characteristicsMedicare coverage decisionsAdjuvant chemotherapyChemotherapy useN1 diseaseMost patientsComorbid conditionsMultivariable analysisRS assayClinical variablesStudy criteriaBlack race
2014
Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007. Journal Of Clinical Oncology 2014, 32: 309-309. DOI: 10.1200/jco.2014.32.30_suppl.309.Peer-Reviewed Original ResearchReceipt of chemotherapyChemotherapy utilizationOncotype DXRisk diseaseBreast cancerODX testingEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerER-positive breast cancerIntermediate-risk diseaseHigh-risk patientsHigh-risk diseasePositive breast cancerBreast cancer populationAdjuvant chemotherapyNCCN guidelinesRisk patientsPathologic featuresRandomized trialsStudy criteriaCancer populationObservational studyRetrospective analysis